Owners, management and financials
CVR: 41319208
DKK -179,735
Gross profit
Net result: DKK -4,440,533
Fogtmann Fosgerau Holding ApS (50-66,65%), Andrew Justin Stewart Coats (5-9,99%)
CVR · view owners
Keld Fogtmann Fosgerau
Board: Anders Mørkeberg Hinsby (chair) and 5 members
CVR · view management
Active
Founded 24 April 2020
CVR · view overview
4 employees
Annual report 2025 · average
Owner registered: Fogtmann Fosgerau Holding ApS
CVR · 22/11/2022
View the full event history
Pephexia Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Keld Fogtmann Fosgerau. The board consists of Anders Mørkeberg Hinsby (chair), Andrew Justin Stewart Coats, Keld Fogtmann Fosgerau and Mats Peter Blom. The company is owned by Fogtmann Fosgerau Holding ApS and Andrew Justin Stewart Coats. According to the 2025 annual report, the company had an average of 4 employees. In 2025, the company reported a gross profit of DKK -179,735 and a net result of DKK -4,440,533 compared with DKK -5,320,870 the year before. Equity in the 2025 report amounted to DKK -19,747,345.
Virksomhedens formål er forskning og udvikling af lægemidler samt anden dermed beslægtet virksomhed efter direktionens skøn.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | - | -4.4 mio. | 2 mio. | -19.7 mio. | 4 | |
| 202401/01/2024 – 31/12/2024 | - | -5.3 mio. | 5.9 mio. | -15.3 mio. | 4 | |
| 202301/01/2023 – 31/12/2023 | - | -5.4 mio. | 5.3 mio. | -12.6 mio. | 3 | |
| 202201/01/2022 – 31/12/2022 | - | -6.7 mio. | 9.7 mio. | -7.1 mio. | 3 | |
| 202101/01/2021 – 31/12/2021 | 626 t. | -4.5 mio. | 4.8 mio. | -2.7 mio. | 0 |
Compared to 1.040 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationThe CVR number of Pephexia Therapeutics ApS is 41319208.
Pephexia Therapeutics ApS is owned by Fogtmann Fosgerau Holding ApS and Andrew Justin Stewart Coats.
The management of Pephexia Therapeutics ApS consists of Keld Fogtmann Fosgerau.
The board of Pephexia Therapeutics ApS consists of Anders Mørkeberg Hinsby, Andrew Justin Stewart Coats and Keld Fogtmann Fosgerau, with Anders Mørkeberg Hinsby as chair.
In 2025, Pephexia Therapeutics ApS reported a gross profit of DKK -179,735.
Pephexia Therapeutics ApS had an average of 4 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
Pephexia Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK -179,735, and the net result was DKK -4,440,533.
Contact info changed: new phone: 50910969, new email: [email protected], new website: www.pephexia.com (May 28, 2026).
As of May 27, 2026, Ricki Boye has joined the board of directors of Pephexia Therapeutics ApS.
Contact info changed: new phone: 50910969, new email: [email protected], new website: www.pephexia.com (May 15, 2026).
Contact info changed: new phone: 50910969, new email: [email protected], new website: www.pephexia.com (April 1, 2026).
Contact info changed: new phone: 50910969, new email: [email protected], new website: www.pephexia.com (March 31, 2026).
Pephexia Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -2,085,438, and the net result was DKK -5,320,870.
Pephexia Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -3,212,128, and the net result was DKK -5,439,731.
As of May 22, 2024, Stefan Dietmar Anker has joined the board of directors of Pephexia Therapeutics ApS.
As of May 22, 2024, Yann Albert André Colardelle has left the board of directors of Pephexia Therapeutics ApS.
Pephexia Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -5,266,259, and the net result was DKK -6,677,466.
As of December 16, 2022, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has been appointed auditor of Pephexia Therapeutics ApS.
As of November 22, 2022, Fogtmann Fosgerau Holding ApS is registered as an owner of Pephexia Therapeutics ApS with an ownership share of 50%.
As of July 7, 2022, Keld Fogtmann Fosgerau has joined the board of directors of Pephexia Therapeutics ApS.
As of July 7, 2022, Anders Mørkeberg Hinsby has joined the board of directors of Pephexia Therapeutics ApS.
As of July 6, 2022, Keld Fogtmann Fosgerau has left the board of directors of Pephexia Therapeutics ApS.
Pephexia Therapeutics ApS has published its annual report for 2021. Revenue came to DKK 626,000, and the net result was DKK -4,532,328.
Pephexia Therapeutics ApS has published its interim report for the period April 24, 2020 – December 31, 2020.
As of November 2, 2020, Keld Fogtmann Fosgerau has joined the board of directors of Pephexia Therapeutics ApS.
As of November 2, 2020, Yann Albert André Colardelle has joined the board of directors of Pephexia Therapeutics ApS.
As of November 2, 2020, Mats Peter Blom has joined the board of directors of Pephexia Therapeutics ApS.
As of November 2, 2020, Andrew Justin Stewart Coats has joined the board of directors of Pephexia Therapeutics ApS.
As of November 2, 2020, is registered as an owner of Pephexia Therapeutics ApS with an ownership share of 5%.
As of April 24, 2020, Keld Fogtmann Fosgerau is registered as director of Pephexia Therapeutics ApS.
Pephexia Therapeutics ApS was founded on April 24, 2020.
Companies in the same industry and area
CVR 40766383
CVR 42597333
CVR 46613139
CVR 44504332
CVR 43917897
